timothy sykes logo
FHTX Stock Slides As Traders Eye Key Support Levels Thumbnail
G Google News

FHTX Stock Slides As Traders Eye Key Support Levels

BRYCE TUOHEY•UPDATED OCT. 1, 2026, 9:18 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Foghorn Therapeutics Inc. faces heightened pressure as trial setback news weighs on outlook, with stocks trading down by -43.14 percent.

Key Takeaways

  • Shares of FHTX have dropped hard from the $4.80 area to the mid-$3s, putting Foghorn Therapeutics Inc. back near prior support.
  • Intraday action shows FHTX repeatedly rejecting spikes over $2 in premarket, signaling heavy overhead supply and cautious trading.
  • Cash of about $68M against modest debt gives Foghorn Therapeutics Inc. runway, even with steep quarterly cash burn.
  • Deep negative margins and losses keep FHTX firmly in high‑risk, story‑driven territory for momentum traders.
  • Chart structure on FHTX suggests a make‑or‑break zone where a bounce or breakdown could trigger fast trading moves.

Candlestick Chart

Live Update At 09:18:18 EDT: On Thursday, October 01, 2026 Foghorn Therapeutics Inc. stock [NASDAQ: FHTX] is trending down by -43.14%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Foghorn Therapeutics Inc., trading under ticker FHTX, is a classic early‑stage biotech name: meaningful cash, little revenue, and heavy losses. For the latest reported quarter ending 2026/06/30, FHTX posted total revenue of about $16.1M but still lost roughly $7.2M. That works out to a basic EPS of -$0.10 on about 70.6M average shares, underscoring how far the company is from profitability.

Margins tell the same story. FHTX shows a gross margin near 100%, which simply reflects that its revenue is collaboration or service‑like rather than product‑heavy, but EBIT margin near -188% and profit margins around -176% make it clear that operating costs overwhelm revenue. Research and development expense of about $18.5M in the quarter is the main driver; Foghorn Therapeutics Inc. is spending aggressively to advance its pipeline.

More Breaking News

On the balance‑sheet side, FHTX holds about $68.1M in cash and $167.6M when you include short‑term investments. Current assets of $170.0M versus current liabilities of $50.6M translate to a current ratio around 3.4. That gives Foghorn Therapeutics Inc. a solid liquidity cushion for now, even though reported stockholders’ equity is negative.

Why Traders Are Watching FHTX Price Action

FHTX has been a grinder on the daily chart. In mid‑September, Foghorn Therapeutics Inc. traded as high as $4.91 and closed near $4.83. Over the next couple of weeks, the stock faded step by step, with closes sliding from the $4.60s into the $3.50s. The most recent daily close around $3.57 marks roughly a 25% pullback from those highs, which is enough to reset weak hands and catch the attention of short‑term traders.

That fade has been controlled rather than a panic crash. Daily ranges on FHTX narrowed from wild swings near the top to tighter candles around $3.50–$3.60. When volatility contracts after a trend, it often sets up the next big move. Traders watching Foghorn Therapeutics Inc. now are focused on whether the $3.50 zone holds as support or breaks and opens the door to another leg down.

The intraday five‑minute data paints a different picture: FHTX has been battling heavy resistance near $2 in premarket trading. Repeated wicks above $2.00–$2.10 faded quickly back toward $1.95–$2.03, showing that every push higher meets supply. Premarket open around $2.50 that washed to $2.04 right away screams failed spike — a pattern day traders in Foghorn Therapeutics Inc. know well.

Put it together and you have a name where longer‑term charts show a pullback from $4–$5 toward prior support, while shorter‑term action shows sellers stepping in on every bounce. That tension is exactly what active traders like to stalk. A convincing reclaim of those intraday $2.10–$2.20 levels could kick off a squeeze, while a clean break of the recent daily lows on FHTX may invite more downside momentum.

Conclusion

For active traders, FHTX sits at the crossroads of weak fundamentals and interesting technicals. Foghorn Therapeutics Inc. is burning serious cash — about $17.9M in free cash flow out the door last quarter — yet it still holds a healthy cash and short‑term investment pile. That combination keeps the story alive, but the negative return on assets near -29% and deeply red margins remind everyone this is a speculative biotech play, not a steady cash machine.

On the chart, FHTX’s slide from the high‑$4 range down toward the mid‑$3s has cooled off earlier momentum. Now the stock is compressing, both on the daily and in intraday premarket action. When a stock like Foghorn Therapeutics Inc. bases after a sharp move, the next break — up or down — often happens faster than traders expect.

The edge comes from preparation, not prediction. As Tim Sykes loves to say, “I’m not here to be right, I’m here to trade the patterns and manage risk.” That mindset lines up with another of his core trading principles: As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.”. Applied to FHTX, that means mapping your key levels on Foghorn Therapeutics Inc., sizing small, and cutting losses quickly if the trade thesis breaks. For disciplined traders, FHTX is less about hoping for a biotech breakthrough and more about respecting the chart and letting price action lead every decision.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”